Navigation Links
Drug Could Make Melanoma More Vulnerable to Chemo
Date:3/6/2009

Compound disabled protein fueling tumor growth, making therapy more effective

FRIDAY, March 6 (HealthDay News) -- A compound that targets and disables a protein found in melanoma tumors may make the deadly skin cancer more vulnerable to chemotherapy, early results of a pilot study show.

Sixteen patients with advanced melanoma on an extremity (feet, hands, etc.) were given the compound ADH-1 intravenously and then underwent chemotherapy by infusion in the affected limb. The melanoma was eradicated in half the patients.

The findings were expected to be presented Friday at the Society of Surgical Oncology annual meeting in Phoenix, and have been accepted for publication in the journal Cancer. The study was funded by Adherex Technologies, which is developing ADH-1.

"These early results are very exciting, because metastatic melanoma is one of the most deadly cancers and one which is typically very unresponsive to therapy," lead author Dr. Georgina Beasley, a surgical resident at the Duke Comprehensive Cancer Center, said in a university news release. "The next step will be to continue testing the efficacy of this treatment in more patients, here and at other centers."

A Phase II trial involving 46 patients has recently completed recruiting participants.

The incidence of melanoma is increasing at a rate faster than any other cancer, and 60,000 new cases of melanoma will be diagnosed in the United States this year, according to background information in the news release.

Melanoma often develops on extremities, and up to 10 percent of patients with extremity melanoma develop multiple recurrences that can't be treated with surgery alone. Melanoma that spreads beyond the primary site is rarely curable, and there are limited treatment options.

More information

The American Academy of Dermatology has more about melanoma.



-- Robert Preidt



SOURCE: Duke Medicine, news release, March 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment
2. Engineered Viruses Could Battle Superbugs
3. Stem cells could halt osteoporosis, promote bone growth
4. TB breakthrough could lead to stronger vaccine
5. Classifying concussions could help kids
6. Vegetable-based drug could inhibit melanoma
7. Report: Many Cancers Could Be Prevented in US
8. Landmark Policy Report: Many Cancers Could Be Prevented Across the Globe
9. Landmark Report: Many Cancers Could be Prevented
10. Economy could reduce colorectal cancer screening rate
11. UCSF Gallo Study Finds Hormone Disorder Drug Could Help Drinkers Stay Sober
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Could Make Melanoma More Vulnerable to Chemo
(Date:5/4/2016)... ... May 04, 2016 , ... NCPDP announced ... on Tuesday with Frank Luntz, sharing a dynamic, bi-partisan environmental scan of healthcare-related ... dive on NCPDP’s model solution to help stem the tide of the opioid ...
(Date:5/4/2016)... NY (PRWEB) , ... May 04, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – is set to return to the esteemed Quaker Ridge Golf Club in ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... The ... Day to recognize chaplains for their valuable support to patients and their families, and ... May 10. , To mark Spiritual Care Day, SCA has sent “Thank You Chaplain” ...
(Date:5/4/2016)... Charles, LA (PRWEB) , ... May 04, 2016 , ... ... Charles, LA area has teamed up with Big Brothers Big Sisters of Southwest Louisiana ... now being accepted here . , Big Brothers Big Sisters of Southwest Louisiana ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... SS&A teamed up with one of the top website design companies to create ... informative legal articles related to the law firm's main practice areas. These practice ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 BiondVax Pharmaceuticals Ltd. ... Ron Babecoff , will be attending the Joseph Gunnar ... . On Thursday, May 5, Dr. Babecoff will ... by Joseph Gunner & Co, taking place at ... that Dr. Babecoff will be using is downloadable from BiondVax,s ...
(Date:5/4/2016)... Jersey , May 4, 2016 ... successful completion of an alternative public offering (APO). This ... owned operating company, Valeritas, Inc. and a private placement ... stock at $5.00 per share. Under the ... May 3, 2016, Valeritas Holdings, Inc. will trade on ...
(Date:5/4/2016)... Research and Markets has ... Keratosis Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Actinic ... Keratosis market valuations and forecast, Actinic Keratosis ...
Breaking Medicine Technology: